151675 - targeting LIN28.pdf (3.12 MB)
Targeting LIN28: A new hope in prostate cancer theranostics
journal contribution
posted on 2023-05-21, 10:31 authored by Shrivastava, G, Aljabali, AAA, Shahcheraghi, SH, Lotfi, M, Madhur ShastriMadhur Shastri, Shukla, SD, Chellappan, DK, Jha, NK, Anand, K, Dureja, H, Pabari, RM, Mishra, V, Almutary, AG, Alnuqaydan, AM, Charbe, N, Prasher, P, Negi, P, Goyal, R, Dua, K, Gupta, G, Serrano-Aroca, A, Bahar, B, Barh, D, Panda, PK, Takayama, K, Lundstorm, K, McCarron, P, Bakshi, H, Tambuwala, MMThe mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.
History
Publication title
Future OncologyVolume
17Issue
29Pagination
3873-3880ISSN
1479-6694Department/School
School of Pharmacy and PharmacologyPublisher
Future Medicine Ltd.Place of publication
United KingdomRights statement
Copyright 2021 The Authors Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/Repository Status
- Open